- Conditions
- Platinum-Resistant Ovarian Carcinoma
- Interventions
- Chimeric Antigen Receptor T-cells, Cyclophosphamide, Fludarabine
- Biological · Drug
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- Duarte, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 258
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Interventions
- FATE-NK100, Interleukin-2
- Biological · Drug
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- 18 Years to 75 Years · Female only
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Ovarian High Grade Serous Adenocarcinoma, Platinum-Resistant Ovarian Carcinoma
- Interventions
- Atovaquone, Biopsy, Computed Tomography, Paracentesis
- Drug · Procedure
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Platinum-resistant Ovarian Cancer, Refractory Ovarian Carcinoma
- Interventions
- CBX-12
- Drug
- Lead sponsor
- Cybrexa Therapeutics
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Tucson, Arizona
- Conditions
- Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Interventions
- docetaxel
- Drug
- Lead sponsor
- Gynecologic Oncology Group
- Network
- Eligibility
- 18 Years and older · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1998
- U.S. locations
- 66
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 53 more
- Conditions
- Ovarian Cancer
- Interventions
- SC-003, SC-003 in combination with ABBV-181
- Drug
- Lead sponsor
- Stemcentrx
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 16
- States / cities
- Fayetteville, Arkansas • Duarte, California • Chicago, Illinois + 12 more
- Conditions
- Ovarian Cancer
- Interventions
- misetionamide (also known as GP-2250)
- Drug
- Lead sponsor
- Persevere Therapeutics Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 4
- States / cities
- Chicago, Illinois • Fairway, Kansas • Boston, Massachusetts + 1 more
- Conditions
- Fallopian Tube High Grade Serous Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma, Ovarian Seromucinous Carcinoma, Primary Peritoneal High Grade Serous Adenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Fallopian Tube Clear Cell Adenocarcinoma, Recurrent Fallopian Tube Endometrioid Adenocarcinoma, Recurrent Fallopian Tube Undifferentiated Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Ovarian Clear Cell Adenocarcinoma, Recurrent Ovarian Endometrioid Adenocarcinoma, Recurrent Ovarian Undifferentiated Carcinoma, Recurrent Platinum-Resistant Fallopian Tube Carcinoma, Recurrent Platinum-Resistant Ovarian Carcinoma, Recurrent Platinum-Resistant Primary Peritoneal Carcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Primary Peritoneal Clear Cell Adenocarcinoma, Recurrent Primary Peritoneal Endometrioid Adenocarcinoma, Recurrent Primary Peritoneal Undifferentiated Carcinoma
- Interventions
- Atezolizumab, Bevacizumab, Computed Tomography, Pegylated Liposomal Doxorubicin Hydrochloride, Quality-of-Life Assessment
- Drug · Biological · Procedure + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 444 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 907
- States / cities
- Anchorage, Alaska • Fairbanks, Alaska • Goodyear, Arizona + 574 more
- Conditions
- Neoplasms, Ovarian
- Interventions
- MORAb-202, Paclitaxel, Pegylated Liposomal Doxorubicin (PLD), Topotecan
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 106 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 10
- States / cities
- Sacramento, California • San Francisco, California • Whittier, California + 7 more
- Conditions
- Ovarian Cancer, Ovarian Carcinoma, Recurrent Ovary Cancer, Recurrent Platinum-Resistant Ovarian Carcinoma
- Interventions
- DT2216, Paclitaxel
- Drug
- Lead sponsor
- Elizabeth Stover, MD, PhD
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts
- Conditions
- Recurrent Ovarian Cancer
- Interventions
- ChemoID assay, Chemotherapy
- Diagnostic Test · Drug
- Lead sponsor
- Cordgenics, LLC
- Industry
- Eligibility
- 18 Years and older · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 3
- States / cities
- Jackson, Mississippi • Charleston, West Virginia • Huntington, West Virginia
- Conditions
- Ovarian Cancer
- Interventions
- Triciribine, Carboplatin
- Drug
- Lead sponsor
- Prescient Therapeutics, Ltd.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
- Interventions
- MM-121, Paclitaxel
- Drug
- Lead sponsor
- Merrimack Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 223 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 10
- States / cities
- Glendale, Arizona • Scottsdale, Arizona • Bakersfield, California + 7 more
- Conditions
- Platinum-resistant Ovarian Cancer
- Interventions
- Rina-S, Paclitaxel, Topotecan, Pegylated liposomal doxorubicin (PLD), Gemcitabine
- Drug
- Lead sponsor
- Genmab
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 584 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 72
- States / cities
- Anchorage, Alaska • Scottsdale, Arizona • Tucson, Arizona + 60 more
- Conditions
- Epithelial Ovarian Cancer
- Interventions
- AZD5335, Mirvetuximab Soravtansine (MIRV), Paclitaxel, Pegylated liposomal Doxorubicin (PLD), Topotecan
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 1,100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 40
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 37 more
- Conditions
- Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
- Interventions
- Atezolizumab, DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Guadecitabine, Laboratory Biomarker Analysis, Poly ICLC
- Drug · Biological · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 17
- States / cities
- Tucson, Arizona • Duarte, California • Sacramento, California + 11 more
- Conditions
- Epithelial Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
- Interventions
- Mirvetuximab Soravtansine, Paclitaxel, Topotecan, Pegylated liposomal doxorubicin
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 453 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 78
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 66 more
- Conditions
- Platinum-resistant Epithelial Ovarian Cancer
- Interventions
- Maveropepimut-S, Cyclophosphamide 50mg
- Other · Drug
- Lead sponsor
- ImmunoVaccine Technologies, Inc. (IMV Inc.)
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 4
- States / cities
- Palo Alto, California • Ocala, Florida • Mineola, New York + 1 more
- Conditions
- BRCA1 Gene Mutation, BRCA2 Gene Mutation, Folate Receptor Alpha Positive, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Uterine Corpus Carcinoma, Recurrent Uterine Serous Carcinoma, Recurrent Uterine Carcinosarcoma, Platinum Resistant Ovarian Cancer
- Interventions
- Laboratory Biomarker Analysis, Mirvetuximab Soravtansine, Pharmacokinetic Study, Rucaparib Camsylate
- Other · Biological · Drug
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Advanced Solid Tumors, Breast Cancer Recurrent, Ovarian Cancer, High-grade Serous Ovarian Carcinoma, Triple Negative Breast Cancer, sqNSCLC, Squamous Non-small-cell Lung Cancer
- Interventions
- ATX-295, ATX-295 and bevacizumab (or biosimilar)
- Drug
- Lead sponsor
- Accent Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 218 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 11
- States / cities
- Aurora, Colorado • Sarasota, Florida • Detroit, Michigan + 8 more
- Conditions
- Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Primary Peritoneal High Grade Serous Adenocarcinoma
- Interventions
- Anetumab Ravtansine, Bevacizumab, Paclitaxel
- Biological · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 22
- States / cities
- Orange, California • Aurora, Colorado • Coral Gables, Florida + 19 more
- Conditions
- COL6A3 Positive, HLA-A*0201 Positive Cells Present, PRAME Positive, Recurrent Ovarian Carcinoma
- Interventions
- Aldesleukin, CD8-Positive T-Lymphocyte, Cyclophosphamide, Leukapheresis, Utomilumab
- Biological · Drug · Procedure
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years to 75 Years · Female only
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Recurrent Epithelial Ovarian Cancer, Recurrent Fallopian Tube Cancer, Recurrent Primary Peritoneal Cancer
- Interventions
- Tivozanib
- Drug
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years to 110 Years · Female only
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2021
- U.S. locations
- 2
- States / cities
- Chicago, Illinois • Warrenville, Illinois
- Conditions
- Ovarian Carcinoma
- Interventions
- Sacituzumab govitecan
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut